GW9508 suppresses chondrogenic differentiation of BMSCs and attenuates heterotopic ossification without significantly affecting osteogenic differentiation

Post-traumatic heterotopic ossification (HO) is a pathological bone-forming disorder characterized by aberrant activation of bone marrow-derived mesenchymal stem cells (BMSCs) and ectopic endochondral ossification; however, effective targeted therapies remain limited. This study investigated the regulatory effects and underlying mechanisms of GW9508, an agonist of free fatty acid receptors GPR40/120, on HO progression. After determining the safe concentration range of GW9508 using a CCK-8 assay, in vitro chondrogenic and osteogenic differentiation models were established to evaluate its effects on BMSC lineage commitment through qRT-PCR, Western blotting, and histological staining. A C57BL/6 mouse Achilles tendon transection model was further used to assess in vivo efficacy by micro-computed tomography, histological analysis, and immunofluorescence staining. GW9508 did not affect BMSC proliferation but significantly reduced the expression of chondrogenic markers Sox9, Col2a1, and Acan at both mRNA and protein levels in a dose-dependent manner, accompanied by decreased cartilage extracellular matrix deposition. In contrast, GW9508 showed no significant effects on osteogenic markers Runx2, ALP, and Sp7 or mineralized nodule formation. In vivo, local administration of GW9508 reduced ectopic bone formation and inhibited both early chondrogenesis and subsequent ossification. Collectively, these findings suggest that GW9508 attenuates HO progression by suppressing the chondrogenic differentiation of BMSCs, thereby limiting the subsequent endochondral ossification process. Under the present in vitro experimental conditions, GW9508 selectively inhibited chondrogenic differentiation without causing significant alterations in osteogenic differentiation. These findings provide new insights into potential therapeutic strategies for post-traumatic HO.

Authors

Institutions

Publication Details

Journal
International Immunopharmacology
Published
2026-11-16
DOI
https://doi.org/10.1016/j.intimp.2026.117698
Primary Topic
Heterotopic Ossification and Related Conditions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

GW9508 suppresses chondrogenic differentiation of BMSCs and attenuates heterotopic ossification without significantly affecting osteogenic differentiation

Xuenong Zou, Lu Lin, Zhenxing He, Zuxin Li et al.
1 links
International Immunopharmacology
Heterotopic Ossification and Related Conditions
article

GW9508 suppresses chondrogenic differentiation of BMSCs and attenuates heterotopic ossification without significantly affecting osteogenic differentiation

Xuenong Zou, Lu Lin, Zhenxing He, Zuxin Li, Haifei Wu, Jiachen Xia, Panxin Liao, Guanglin Ji
article en

Abstract

Post-traumatic heterotopic ossification (HO) is a pathological bone-forming disorder characterized by aberrant activation of bone marrow-derived mesenchymal stem cells (BMSCs) and ectopic endochondral ossification; however, effective targeted therapies remain limited. This study investigated the regulatory effects and underlying mechanisms of GW9508, an agonist of free fatty acid receptors GPR40/120, on HO progression. After determining the safe concentration range of GW9508 using a CCK-8 assay, in vitro chondrogenic and osteogenic differentiation models were established to evaluate its effects on BMSC lineage commitment through qRT-PCR, Western blotting, and histological staining. A C57BL/6 mouse Achilles tendon transection model was further used to assess in vivo efficacy by micro-computed tomography, histological analysis, and immunofluorescence staining. GW9508 did not affect BMSC proliferation but significantly reduced the expression of chondrogenic markers Sox9, Col2a1, and Acan at both mRNA and protein levels in a dose-dependent manner, accompanied by decreased cartilage extracellular matrix deposition. In contrast, GW9508 showed no significant effects on osteogenic markers Runx2, ALP, and Sp7 or mineralized nodule formation. In vivo, local administration of GW9508 reduced ectopic bone formation and inhibited both early chondrogenesis and subsequent ossification. Collectively, these findings suggest that GW9508 attenuates HO progression by suppressing the chondrogenic differentiation of BMSCs, thereby limiting the subsequent endochondral ossification process. Under the present in vitro experimental conditions, GW9508 selectively inhibited chondrogenic differentiation without causing significant alterations in osteogenic differentiation. These findings provide new insights into potential therapeutic strategies for post-traumatic HO.

International ImmunopharmacologyVol. 191(Pt 2)
Sun Yat-sen University (CN), Gannan Medical University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), First Affiliated Hospital of Gannan Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Heterotopic Ossification and Related Conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon